Financings in Brief: Cyberonics
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics: Grosses $47.6 mil. from secondary offering of 3 mil. shares at $15.875 per share. A portion of the proceeds will be used to boost manufacturing capacity and to develop sales, marketing and distribution capabilities. The Webster, Texas firm received FDA approval in July for its NCP NeuroCybernetic Prosthesis implantable vagus nerve stimulator to treat epilepsy ("The Gray Sheet" July 21, p. 8). Remaining proceeds will be used for further product development, clinical trials and "general corporate purposes," the firm states. Underwriters Montgomery Securities and Piper Jaffray hold an overallotment option for 450,000 additional shares...
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.